Comparison of Nasal and Nasopharyngeal Swabs for Influenza Detection in Adults

  1. Edward A. Belongia, MD*
  1. *Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA
  2. Current Affiliation: Senior Analyst, Abt Associates, Atlanta, Georgia, USA
  3. Core Laboratory, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA
  4. §Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  1. Corresponding Author: Stephanie Irving, MHS; Abt Associates; 2200 Century Parkway, Suite 950; Atlanta, GA 30345; Tel: 404.946.6309; Fax: 404.965.3065; E-mail: stephanie_irving{at}abtassoc.com

Abstract

Objective Examine differences in the detection of influenza by specimen and test type using paired nasal and nasopharyngeal swabs.

Design Prospective study

Setting Enrollment took place between January and March 2007 in a central Wisconsin population.

Participants Adult patients were screened and enrolled by trained research coordinators following medical encounters for acute respiratory illnesses of <10 days duration.

Methods Paired nasal and nasopharyngeal swabs were collected from consenting patients and tested by both real-time reverse transcriptase polymerase chain reaction (rRT-PCR) and viral culture. A composite measure of positivity was used as the gold standard; cases included any positive result by rRT-PCR or viral culture from either specimen type.

Results Paired samples were collected from 240 adults; 33 (14%) individuals tested positive for influenza by rRT-PCR. Using rRT-PCR, the sensitivity of the nasal swab was 89% (95% CI, 78%-99%) and the sensitivity of the nasopharyngeal swab was 94% (95% CI, 87%-100%), compared to a composite gold standard.

Conclusion Test sensitivity did not vary significantly by swab type when using a highly sensitive molecular diagnostic test, but power was limited to detect modest differences.

Keywords

Footnotes

  • Financial Disclosure: Funding for this research was provided by a cooperative agreement with the Centers for Disease Control and Prevention, Atlanta, GA (1 U01 CI000192-01).

| Table of Contents